BioAge Labs Inc., a clinical-stage biotechnology company, reported its financial results for the first quarter of 2025. The company reported a net loss of $12.9 million for the quarter ended March 31, 2025, compared to a net loss of $13.0 million for the same period in 2024. Research and development expenses increased to $11.1 million from $9.3 million in the previous year, primarily due to a $2.7 million rise in direct costs associated with IND-enabling activities for BGE-102. General and administrative expenses also rose to $6.8 million from $3.5 million, largely due to a $2.0 million increase in personnel-related expenses, including stock-based compensation. BioAge Labs reported approximately $335.1 million in cash, cash equivalents, and marketable securities as of March 31, 2025, and estimates that this will fund operations and capital expenses through 2029. Significant business updates include the advancement of BGE-102, an oral, brain-penetrant NLRP3 inhibitor for obesity, with initial clinical data expected in the second half of 2025. Additionally, BioAge announced a new strategic collaboration with Lilly ExploR&D to expand its therapeutic approach to novel metabolic aging targets. The company is also progressing with its preclinical next-generation APJ agonists for obesity, aiming to nominate a development candidate by the end of 2025.